STAT

MAY 16, 2023

STAT+ subscribers get access to exclusive virtual pop-up conversations with STAT reporters on key stories of the moment, and biotech, pharma and health tech leaders on breakthroughs.   Please note: Speakers and topics are subject to change! Register below for the upcoming conversation.

46

46

Pharmaceutical Technology

OCTOBER 18, 2022

Oculis has signed a definitive business combination agreement with special purpose acquisition company (SPAC) European Biotech Acquisition (EBAC). OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment, while OCS-05 is an activator of serum-glucocorticoid kinase 2.

59

59

STAT

DECEMBER 1, 2022

We cover all these topics and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. The first FDA-approved fecal microbiome drug. And a stinging defeat for Big Pharma’s lobbying arm.

FDA 63

FDA 63

ISPE

APRIL 12, 2023

A Closer Look at Paperless Validation’s Impact on Biotech Trudy Patterson Wed, 04/12/2023 - 07:34 iSpeak Blog iSpeak A Closer Look at Paperless Validation’s Impact on Biotech Steven Thompson 12 April 2023 The impact of paperless validation on the biotechnology industry is massive, and the overall effect is growing as adoption increases.

Documentation 98

Documentation FDA 98

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Bringing theranostics to prostate cancer.

98

98

pharmaphorum

NOVEMBER 2, 2021

The approach has become a hot topic in biopharma with a string of big ticket partnerships over the last couple of years, including a $2.4 Alongside Novartis, BioGeneration Ventures (BGV) has also come onboard as a new investor, with general partner Oskar Slotboom joining the biotech’s board.

97

97

Pharmaceutical Technology

MAY 22, 2023

The US Food and Drug Administration (FDA) has granted approval for Krystal Biotech’s Vyjuvek (beremagene geperpavec-svdt) to treat dystrophic epidermolysis bullosa (DEB) in patients aged six months and above. Vyjuvek is a non-invasive, topical, re-dosable gene therapy that delivers functional human COL7A1 gene copies to offer wound healing.

FDA 52

FDA 52

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). Topic sponsors are not involved in the creation of editorial content.

Compounding 98

Compounding 98

pharmaphorum

JANUARY 13, 2022

AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. It’s not the big pharma’s first foray into the transcription factor area.

58

58

pharmaphorum

AUGUST 28, 2020

Italian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new approach to treating acne in nearly 40 years. The biotech isn’t revealing how much it intends to charge for the new medicine, saying it will do so closer to launch later this year.

FDA 52

FDA Immunization 52

pharmaphorum

AUGUST 17, 2021

Watch the video below to hear more on those topics and to find out more about PureTech’s interest in digital health, how that lines up alongside its focus on medicines, and some of the biotech company’s key partnerships. About the interviewee. Daphne Zohar is PureTech’s founder and CEO and a member of its board of directors.

Communication 110

Communication Immunization 110

pharmaphorum

OCTOBER 18, 2022

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.

58

58

pharmaphorum

AUGUST 31, 2022

Futura Medical’s development of a topical treatment for erectile dysfunction (ED) is approaching the finish line in the US, as the UK biotech reports confirmatory phase 3 data ahead of an FDA filing later this month. ” The post Futura eyes FDA filing as topical ED drug passes phase 3 test appeared first on.

FDA 52

FDA 52

The FDA Law Blog

MARCH 6, 2024

The American Conference Institute (“ACI”) will be hosting a series of go-to forums on critical topics including novel therapeutics, cosmetics/personal care products and Paragraph IV disputes. HP&M is proud to have our professionals participating in these important events. On March 20-21, Counsel John W.M.

FDA 59

FDA Pharmaceutical Companies Pharmaceutical Companies 59

Pharmaceutical Technology

APRIL 3, 2023

Sartorius , through its French listed sub-group Sartorius Stedim Biotech , has signed an agreement to acquire Polyplus for €2.4bn ($2.6bn). Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

98

98

pharmaphorum

OCTOBER 28, 2022

In June, NHSE and NICE published details on the Innovative Medicines Fund, which will help improve patient access to cutting-edge medicines, with a particular focus on rare diseases, and ensure global pharmaceutical and biotech organisations continue to prioritise the UK as a launch destination.

120

120

ISPE

MAY 10, 2023

He is also Chief Quality Officer at Evive Biotech, responsible for all aspects of quality for the company, ensuring safety and efficacy, making critical quality decisions, and keeping the company up to date with new regulations. I was fortunate to be groomed by many biotech industry pioneers. After I obtained my Ph.D.

Method Validation 52

Method Validation FDA 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

Topic sponsors are not involved in the creation of editorial content. The post Rocket agrees to acquire biotech firm Renovacor appeared first on Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

59

59

pharmaphorum

AUGUST 19, 2022

The German pharma acquired rights to the TRPV1 agonist also known as MTX-071 last year when it acquired Swiss biotech Mestex, and has started dosing patients in one of three planned phase 3 trials in osteoarthritis of the knee.

Compounding 52

Compounding 52

Roots Analysis

SEPTEMBER 1, 2023

In the fiercely competitive landscape of the pharma and biotech industries, standing out from the crowd is crucial for success. In this blog post, I’ll explore how pharma / biotech companies can leverage the blue ocean and red ocean strategy to make waves in the market. How Can Pharma / Biotech Companies Use Blue Red Ocean Strategy?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Hospitals 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Topic sponsors are not involved in the creation of editorial content.

Communication 96

Communication 96

pharmaphorum

OCTOBER 9, 2018

Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients. The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though.

52

52

ISPE

MARCH 22, 2023

The keynote sessions will be followed by a panel discussion to include regulatory agency participation.

FDA 98

FDA 98

pharmaphorum

NOVEMBER 25, 2022

The pain products complement the German drugmaker’s current portfolio which includes a topical capsaicin product called Qutenza for post-shingles nerve pain and diabetic nerve pain affecting the feet, along with non-opioid analgesic resiniferatoxin which recently advanced into phase 3 testing in patients with osteoarthritis.

52

52

Pharmaceutical Technology

JUNE 8, 2023

The companies will offer a comprehensive suite of cell therapy services to biotech, pharmaceutical and government entities, and to hospitals. Topic sponsors are not involved in the creation of editorial content. The core objective of the collaboration is to make the therapies affordable and accessible to patients.

Vaccines 52

Vaccines Immunization Hospitals 52

Pharmaceutical Technology

DECEMBER 27, 2022

Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight. You can sign up for newsletters to never miss the latest news on pharma and biotech, clinical trial strategy and operations , and medical devices. See you in 2023!

Vaccines 122

Vaccines 122

Pharmaceutical Technology

MAY 17, 2023

At a lively panel at Financial Times US Pharma and Biotech Summit on May 16, panellists were at odds over whether the new legislation would improve treatment affordability or stifle pharma innovation. Insulin affordability has continued to prove a hot button topic as major pricing reforms are on the way.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies FDA 52

Pharmaceutical Technology

MAY 3, 2023

Janssen Biotech and the Cellular Biomedicine Group (CBMG) have entered a global collaboration and licence agreement for the development of next-generation chimeric antigen receptor (CAR) T-cell therapies to treat B-cell malignancies. Topic sponsors are not involved in the creation of editorial content.

FDA 59

FDA 59

pharmaphorum

AUGUST 27, 2020

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of the drug. Now, Dermavant is only waiting for results of a long-term safety trial called PSOARING 3 before it moves ahead with a marketing application to the FDA.

FDA 52

FDA 52

Pharmaceutical Technology

JANUARY 20, 2023

However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. On January 4, the company announced plans to acquire Japanese biotech OriCiro Genomics in an $85 million deal. In 2021, Moderna had a net income of $12.2

Vaccines 98

Vaccines Communication FDA 98

ISPE

MARCH 30, 2023

Mark Proctor, Senior Director, Site Operations at AstraZeneca will present a range of topics across key elements of the biopharmaceutical supply eco-system, illustrated with in-use cases and important lessons learned along the way. Greenfield facilities that have been the first to embrace the tools of Pharma 4.0 Industry 4.0,

Documentation 98

Documentation 98

pharmaphorum

APRIL 5, 2022

“We designed the programme to touch on the topics that we believe everyone in the industry should at least be aware of. This will allow participants to revisit and review key topics around the heavy demands of their professional responsibilities. He is author of 100+ contributions on the topic of innovation in healthcare.

123

123

pharmaphorum

APRIL 7, 2021

Jan van de Winkel has overseen one of biotech’s big success stories since he took over Genmab’s CEO in 2010. He spoke to pharmaphorum’s news editor Richard Staines to outline his plans to create a European biotech powerhouse. . The last ten years has seen Denmark’s Genmab become one of biotech’s big success stories. billion). “It

Chemotherapy 73

Chemotherapy Hospitals Vaccines 73

pharmaphorum

FEBRUARY 7, 2019

Topics to be covered include: •Highlights of the 10-Year Plan and the second Sector Deal •Progress with the current Life Sciences Industrial Strategy, the Sector Deal and plans for 2019 •The NHS innovation uptake agenda •Maintaining UK attractiveness for inward global pharma and biotech investment

52

52

pharmaphorum

NOVEMBER 1, 2022

Further topics to be examined comprise of novel RNA modalities encompassing self-amplifying RNA, saRNA, circular RNA, lnc RNA and many more. We will also explore the latest trends in novel RNA therapies, including developments in AI modelling and small molecule modulation of RNA.

52

52

ISPE

SEPTEMBER 28, 2023

All these factors and more have transformed California into a leading destination for life sciences facilities, making the state as well known for medical breakthroughs and biotech as it is for telecommunications and software. The Golden State offers profound opportunities as medical and biotech research trajectories continue to center there.

Hospitals 98

Hospitals Documentation Pharmaceutical Companies Pharmaceutical Companies 98

pharmaphorum

DECEMBER 14, 2020

The post 5th Microbiome Movement – Drug Development Summit Europe 2021 appeared first on.

52

52